Chronic Pain and Addiction

Editor(s): Clark M.R. (Baltimore, Md.) 
Treisman G.J. (Baltimore, Md.) 
Table of Contents
Vol. 30, 2011
Section title: Paper
Clark MR, Treisman GJ (eds): Chronic Pain and Addiction. Adv Psychosom Med. Basel, Karger, 2011, vol 30, pp 92–112

Optimizing Treatment with Opioids and Beyond

Clark M.R. · Treisman G.J.
Departments of aPsychiatry and Behavioral Sciences and bMedicine, The Johns Hopkins University School of Medicine, and cChronic Pain Treatment Program and dAIDS Psychiatry Service, The Johns Hopkins Medical Institutions, Baltimore, Md., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Patients with both chronic pain and substance use disorders offer special challenges and opportunities. They represent a large number of patients with significant costs to themselves and society that translate into poor outcome. The challenges in defining addiction in patients with chronic pain, particularly in those treated with chronic opioid therapy, have distracted the healthcare community from designing effective treatment programs. Traditional treatment programs for chronic pain disorders or substance use disorders are incapable of addressing the issues of the patients’ ‘other’ problem. Treatment devolves to prescribing opioid medications with the belief that both disorders will be treated at least in part, which is deemed better than receiving no treatment at all. Patients are actually concerned about the risks of this type of treatment, and even if it did offer significant benefits, physicians demonstrate a lack of knowledge and skill in administering opioids to these patients. The inadequate treatment of either chronic pain or addiction interferes with the treatment of the other condition and necessitates the design of new treatment paradigms. A new approach to patients with both chronic pain and addiction should start with an evaluation and formulation of these patients to determine the different domains that contribute to their disability (diseases, dimensions, behaviors, life stories). A comprehensive formulation provides the appropriate platform for the implementation of an integrated program of therapy for both conditions that can be intensified to provide more, rather than less, care for the patient that does not meet the goals of functional rehabilitation.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Fleming M Balousek S Klessig C Mundt M Brown D: Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007; 8: 573-582
  2. Rosenblum A Joseph H Fong C Kipnis S Cleland C Portenoy RK: Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289: 2370-2378
  3. Peles E Schreiber S Gordon J Adelson M: Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain 2005; 113: 340-346
  4. Nickel R Raspe HH: Chronic pain: epidemiology and health care utilization (in German). Nervenarzt 2001; 72: 897-906
  5. Ospina M Harstall C: Prevalence of chronic pain: an overview. Health Technology Assessment Report No 29. 2002.;
  6. Verhaak PF Kerssens JJ Dekker J Sorbi MJ Bensing JM: Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998; 77: 231-239
  7. Elliott AM Smith BH Hannaford PC Smith WC Chambers WA: The course of chronic pain in the community: results of a 4-year follow-up study. Pain 2002; 99: 299-307
  8. Mäntyselkä PT Turunen JH Ahonen RS Kumpusalo EA: Chronic pain and poor self-rated health. JAMA 2003; 290: 2435-2442
  9. Stewart WF Ricci JA Chee E Morganstein D Lipton R: Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290: 2443-2454
  10. Brands B Blake J Sproule B Gourlay D Busto U: Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend 2004; 73: 199-207
  11. Dowling LS Gatchel RJ Adams LL Stowell AW Bernstein D: An evaluation of the predictive validity of the Pain Medication Questionnaire with a heterogeneous group of patients with chronic pain. J Opioid Manag 2007; 3: 257-266
  12. Mertens JR Lu YW Parthasarathy S Moore C Weisner CM: Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: comparison with matched controls. Arch Intern Med 2003; 163: 2511-2517
  13. Portenoy RK Dole V Joseph H Lowinson J Rice C Segal S Richman BL: Pain management and chemical dependency: evolving perspectives. JAMA 1997; 278: 592-593
  14. Scimeca MM Savage SR Portenoy R Lowinson J: Treatment of pain in methadone-maintained patients. Mt Sinai J Med 2000; 67: 412-422
  15. Cohen MJ Jasser S Herron PD Margolis CG: Ethical perspectives: opioid treatment of chronic pain in the context of addiction. Clin J Pain 2002; 18: ((suppl 4)) S99-S107
  16. Drug Enforcement Administration A joint statement from 21 health organizations and the Drug Enforcement Administration. Promoting pain relief and preventing abuse of pain medications: a critical balancing act. J Pain Symptom Manage 2002; 24: 147
  17. Nicholson B: Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63: 17-32
  18. Trafton JA Oliva EM Horst DA Minkel JD Humphreys K: Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment. Drug Alcohol Depend 2004; 73: 23-31
  19. Compton P Darakjian J Miotto K: Screening for addiction in patients with chronic pain and ‘problematic’ substance use: evaluation of a pilot assessment tool. J Pain Symptom Manage 1998; 16: 355-363
  20. Miotto K Compton P Ling W Conolly M: Diagnosing addictive disease in chronic pain patients. Psychosomatics 1996; 37: 223-235
  21. Robinson RC Gatchel RJ Polatin P Deschner M Noe C Gajraj N: Screening for problematic prescription opioid use. Clin J Pain 2001; 17: 220-228
  22. Savage SR: Assessment for addiction in paintreatment settings. Clin J Pain 2002; 18: S28-S38
  23. Højsted J Sjøgren P: Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007; 11: 490-518
  24. Portenoy RK: Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11: 203-217
  25. Passik SD Kirsh KL: Managing pain in patients with aberrant drug-taking behaviors. J Support Oncol 2005; 3: 83-86
  26. Passik SD Kirsh KL Whitcomb L Schein JR Kaplan MA Dodd SL Kleinman L Katz NP Portenoy RK: Monitoring outcomes during long-term opioid therapy for noncancer pain: results with the Pain Assessment and Documentation Tool. I Opioid Manag 2005; 1: 257-266
  27. Portenoy RK: Appropriate use of opioids for persistent non-cancer pain. Lancet 2004; 364: 739-740
  28. Savage SR: Addiction in the treatment of pain: significance, recognition and management. J Pain Symptom Manage 1993; 8: 265-278
  29. Sees KL Clark HW: Opioid use in the treatment of chronic pain: assessment of addiction. J Pain Symptom Manage 1993; 8: 257-264
  30. Cicero TJ Dart RC Inciardi JA Woody GE Schnoll S Muñoz A: The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS). Pain Med 2007; 8: 157-170
  31. Olsen Y Daumit GL Ford DE: Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain 2006; 7: 223-235
  32. Gilson AM Ryan KM Joranson DE Dahl JL: A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004; 28: 176-188
  33. Cicero TJ Inciardi JA Muñoz A: Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6: 662-672
  34. Cicero TJ Inciardi JA Surratt H: Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Drug Alcohol Depend 2007; 91: 115-120
  35. Lamb E: Top 200 prescription drugs of 2007. Pharm Times 2008; 74: 20-23
  36. Smith MY Schneider MF Wentz A Hughes A Haddox JD Dart R: Quantifying morbidity associated with the abuse and misuse of opioid analgesics: a comparison of two approaches. Clin Toxicol 2007; 45: 23-30
  37. Cicero TJ Inciardi JA: Diversion and abuse of methadone prescribed for pain management. JAMA 2005; 293: 297-298
  38. Brown RL Patterson JJ Rounds LA Papasouliotis O: Substance abuse among patients with chronic back pain. J Fam Pract 1996; 43: 152-160
  39. Aronoff GM: Opioids in chronic pain management: is there a significant risk of addiction?. Curr Rev Pain 2000; 4: 112-121
  40. Fishbain D Cutler R Rosomoff H: Comorbid psychiatric disorders in chronic pain patients. Pain Clin 1998; 11: 79-87
  41. Portenoy RK Foley KM: Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986; 25: 171-186
  42. Taub A: Opioid analgesics in the treatment of chronic intractable pain on non-neoplastic origin. Kitahata LM Collins D: Narcotic Analgesics in Anesthesiology. Baltimore, Williams and Wilkins, 1982; 199-208
  43. Jamison RN Kauffman J Katz NP: Characteristics of methadone maintenance patients with chronic pain. J Pain Symptom Manage 2000; 19: 53-62
  44. Larson MJ Paasche-Orlow M Cheng DM Lloyd-Travaglini C Saitz R Samet JH: Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. Addiction 2007; 102: 752-760
  45. Fishbain DA Cole B Lewis J Rosomoff HL Rosomoff RS: What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9: 444-459
  46. Moore TM Jones T Browder JH Daffron S Passik SD: A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med 2009; 10: 1426-1433
  47. Michna E Ross EL Hynes WL Nedeljkovic SS Soumekh S Janfaza D Palombi D Jamison RN: Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004; 28: 250-258
  48. Højsted J Nielsen PR Guldstrand SK Frich L Sjøgren P: Classification and identification of opioid addiction in chronic pain patients. Eur J Pain 2010; 14: 1014-1020
  49. Kirsh KL Whitcomb LA Donaghy K Passik SD: Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study. Clin J Pain 2002; 18: S52-S60
  50. Weaver M Schnoll S: Abuse liability in opioid therapy for pain treatment in patients with an addiction history. Clin J Pain 2002; 18: S61-S69
  51. Potter JS Hennessy G Borrow JA Greenfield SF Weiss RD: Substance use histories in patients seeking treatment for controlled-release oxycodone dependence. Drug Alcohol Depend 2004; 76: 213-215
  52. Eisenberg E McNicol ED Carr DB: Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005; 293: 3043-3052
  53. Furlan AD Sandoval JA Mallis-Gagnon A Tunks E: Opioids for chronic noncancer pain: a metaanalysis of effectiveness and side effects. Can Med Assoc J 2006; 174: 1589-1594
  54. Noble M Tregear SJ Treadwell JR Schoelles K: Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008; 35: 214-228
  55. Devulder J Richarz U Nataraja SH: Impact of long-term use of opioids on quality of life in patients with chronic nonmalignant pain. Curr Med Res Opin 2005; 84: S42-S55
  56. Ballantyne JC Mao J: Opioid therapy for chronic pain. N Engl J Med 2003; 349: 1943-1953
  57. Eriksen J Sjøgren P Bruera E Ekholm O Rasmussen NK: Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006; 125: 172-179
  58. Fields HL: Should we be reluctant to prescribe opioids for chronic non-malignant pain?. Pain 2007; 129: 233-234
  59. Kalso E Edwards JE Moore RA McQuay HJ: Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-380
  60. Franklin GM Mai J Wickizer T Turner JA Fulton-Kehoe D Grant L: Opioid dosing trends and mortality in Washington State workers’ compensation, 1996-2002. Am J Ind Med 2005; 48: 91-99
  61. Chou R Fanciullo GJ Fine PG Miaskowski C Passik SD Portenoy RK: Opioids for chronic non-cancer pain: prediction and identification of aberrant drug-related behaviors - a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10: 131-146
  62. Passik SD Kirsh KL Donaghy KB Portenoy RK: Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006; 22: 173-181
  63. von Korff M Saunders K Thomas Ray G Boudreau D Campbell C Merrill J Sullivan MD Rutter CM Silverberg MJ Banta-Green C Weisner C: De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008; 24: 521-527
  64. McCracken LM Hoskins J Eccleston C: Concerns about medication and medication use in chronic pain. J Pain 2006; 7: 726-734
  65. Schieffer BM Pham Q Labus J Baria A van Vort W Davis P Davis F Naliboff BD: Pain medication beliefs and medication misuse in chronic pain. J Pain 2005; 6: 620-629
  66. Karasz A Zallman L Berg K Gourevitch M Selwyn P Amsten JH: The experience of chronic severe pain in patients undergoing methadone maintenance treatment. J Pain Symptom Manage 2004; 28: 517-525
  67. Sullivan MD von Korff M Banta-Green C Merrill JO Saunders K: Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain 2010; 149: 345-353
  68. Noble M Treadwell JR Tregear SJ Coates VH Wiffen PJ Akafomo C Schoelles KM: Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; 20: CD006605
  69. Dworkin RH Turk DC Wyrwich KW Beaton D Cleeland CS Farrar JT Haythornthwaite JA Jensen MP Kerns RD Ader DN Brandenburg N Burke LB Cella D Chandler J Cowan P Dimitrova R Dionne R Hertz S Jadad AR Katz NP Kehlet H Kramer LD Manning DC McCormick C McDermott MP McQuay HJ Patel S Porter L Quessy S Rappaport BA Rauschkolb C Revicki DA Rothman M Schmader KE Stacey BR Stauffer JW von Stein T White RE Witter J Zavisic S: Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: impact recommendations. J Pain 2008; 9: 105-121
  70. Pflughaupt M Scharnagel R Gossrau G Kaiser U Koch T Sabatowski R: Physicians’ knowledge and attitudes concerning the use of opioids in the treatment of chronic cancer and non-cancer pain (in German). Schmerz 2010; 24: 267-275
  71. Wolfert MZ Gilson AM Dahl JL Cleary JF: Opioid analgesics for pain control: Wisconsin physicians’ knowledge, beliefs, attitudes, and prescribing practices. Pain Med 2010; 11: 425-434
  72. Upshur CC Luckmann RS Savageau JA: Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med 2006; 21: 652-655
  73. Wasan AD Correll DJ Kissin I O’Shea S Jamison RN: Iatrogenic addiction in patients treated for acute or subacute pain: a systematic review. J Opioid Manag 2006; 2: 16-22
  74. Gilson AM Maurer MA Joranson DE: State medical board members’ beliefs about pain, addiction, and diversion and abuse: a changing regulatory environment. J Pain 2007; 8: 682-691
  75. Breivik H Collett B Ventafridda V Cohen R Gallacher D: Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333
  76. Galvez R: Variable use of opioid pharmacotherapy for chronic noncancer pain in Europe: causes and consequences. J Pain Palliat Care Pharmacother 2009; 23: 346-356
  77. Ziegler SJ Lovrich NP: Pain relief, prescription drugs, and prosecution: a four-state survey of chief prosecutors. J Law Med Ethics 2003; 31: 75-100
  78. Haller DL Acosta MC: Characteristics of pain patients with opioid-use disorder. Psychosomatics 2010; 51: 257-266
  79. Baldacchino A Gilchrist G Fleming R Bannister J: Guilty until proven innocent: a qualitative study of the management of chronic non-cancer pain among patients with a history of substance abuse. Addict Behav 2010; 35: 270-272
  80. Chapman CR Lipschitz DL Angst MS Chou R Denisco RC Donaldson GW Fine PG Foley KM Gallagher RM Gilson AM Haddox JD Horn SD Inturrisi CE Jick SS Lipman AG Loeser JD Noble M Porter L Rowbotham MC Schoelles KM Turk DC Volinn E von Korff MR Webster LF Weisner CM: Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain 2010; 11: 807-829
  81. Harris JM Jr Elliott TE Davis BE Chabal C Fulginiti JV Pine PG: Educating generalist physicians about chronic pain: live experts and online education can provide durable benefits. Pain Med 2008; 9: 555-563
  82. Harris JM Jr Fulginiti JV Gordon PR Elliott TE Davis BE Chabal C Kutob RM: KnowPain-50: a tool for assessing physician pain management education. Pain Med 2008; 9: 542-554
  83. Passik SD: Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009; 84: 593-601
  84. Ehde DM Jensen MP Engel JM Turner JA Hoffman AJ Cardenas DD: Chronic pain secondary to disability: a review. Clin J Pain 2003; 19: 3-17
  85. Foley K: Pain in the elderly. Hazzard WR Bierman EL Blass JP Ettinger W Halter J: Principles of Geriatric Medicine and Gerontology 3 New York, McGraw-Hill, 1994; 126-149
  86. Gordon RS: Pain in the elderly. JAMA 1979; 241: 2191-2192
  87. Currie SR Hodgins DC Crabtree A Jacobi J Armstrong SJ: Outcome from integrated pain management treatment for recovering substance abusers. Pain 2003; 4: 91-100
  88. Fuller CM Borrell LN Latkin CA Galea S Ompad DC Strathdee SA Vlohov D: Effects of race, neighborhood, and social network on age at initiation of injection drug use. Am J Public Health 2005; 95: 689-695
  89. Kidorf M Brooner RK: Special section - the most critical unresolved issues associated with contemporary vocational rehabilitation for substance users: the critical relationship between employment services and patient motivation. Subst Use Misuse 2004; 39: 2611-2614
  90. Kidorf M Brooner RK King VL Stoller KB Wertz J: Predictive validity of cocaine, benzodiazepine, and alcohol dependence diagnoses. J Consult Clin Psychol 1998; 66: 168-173
  91. Kidorf M Disney ER King VL Neufeld K Beilenson PL Brooner RK: Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend 2004; 74: 115-122
  92. Kidorf M Neufeld K Brooner RK: Combining stepped-care approaches with behavioral reinforcement to motivate employment in opioid-dependent outpatients. Subst Use Misuse 2004; 39: 2215-2238
  93. Kidorf M King VL Neufeld K Stoller KB Peirce J Brooner RK: Involving significant others in the care of opioid-dependent patients receiving methadone. J Subst Abuse Treat 2005; 29: 19-27
  94. Chou R Fanciullo GJ Fine PG Adler JA Ballantyne JC Davies P Donovan MI Fishbain DA Foley KM Fudin J Gilson AM Kelter A Mauskop A O’Connor PG Passik SD Pasternak GW Portenoy RK Rich BA Roberts RG Todd KH Miaskowski C: American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-130
  95. Manchikanti L Benyamin R Datta S Vallejo R Smith H: Opioids in chronic noncancer pain. Expert Rev Neurother 2010; 10: 775-789
  96. Smith HS Kirsh KL Passik SD: Chronic opioid therapy issues associated with opioid abuse potential. J Opioid Manag 2009; 5: 287-300
  97. Jamison RN Butler SF Budman SH Edwards RR Wasan AD: Gender differences in risk factors for aberrant prescription opioid use. J Pain 2010; 11: 312-320
  98. Wasan AD Butler SF Budman SH Fernandez K Weiss RD Greenfield S Jamison RN: Does report of craving opioid medication predict aberrant drug behavior among chronic pain patients? Clin J Pain 2009; 25:193-198.
  99. Dersh J Polatin PB Gatchel RJ: Chronic pain and psychopathology: research findings and theoretical considerations. Psychosom Med 2002; 64: 773-786
  100. Fishbain DA Goldberg M Meagher BR Steele R Rosomoff H: Male and female chronic pain patients categorized by DSM-III psychiatric diagnostic criteria. Pain 1986; 26: 181-197
  101. Harter M Reuter K Weisser B Schretzmann B Aschenbrenner A Bengel J: A descriptive study of psychiatric disorders and psychosocial burden in rehabilitation patients with musculoskeletal diseases. Arch Phys Med Rehabil 2002; 83: 461-468
  102. Gureje O Simon GE von Korff M: A cross-national study of the course of persistent pain in primary care. Pain 2001; 92: 195-200
  103. Bair MJ Wu J Damush TM Sutherland JM Kroenke K: Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med 2008; 70: 890-897
  104. Katon W Sullivan M Walker E: Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma and personality traits. Ann Intern Med 2001; 134: 917-925
  105. Brooner RK King VL Kidorf M Schmidt CW Bigelow GE: Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997; 54: 71-80
  106. Khantzian EJ Treece C: DSM-III psychiatric diagnosis of narcotic addicts. Arch Gen Psychiatry 1985; 42: 1067-1071
  107. Geisser ME Cano A Foran H: Psychometric properties of the mood and anxiety symptom questionnaire in patients with chronic pain. Clin J Pain 2006; 22: 1-9
  108. Wasan AD Butler SF Budman SH Benoit C Fernandez K Jamison RN: Psychiatric history and psychological adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 2007; 23: 307-315
  109. Sullivan MD Edlund MJ Steffick D Unützer J: Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005; 119: 95-103
  110. Manchikanti L Giordano J Boswell M Fellows B Manchukonda R Pampati V: Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. J Opioid Manag 2007; 3: 89-100
  111. Reid MC Engles-Horton LL Weber MB Kerns RD Rogers EL O’Connor PG: Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002; 17: 173-179
  112. Breckenridge J Clark JD: Patient characteristics associated with opioid versus nonsteroidal antiinflammatory drug management of chronic low back pain. J Pain 2003; 4: 344-350
  113. Braden JB Sullivan MD Ray GT Saunders K Merrill J Silverberg MJ Rutter CM Weisner C Banta-Green C Campbell C von Korff M: Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. Gen Hosp Psychiatry 2009; 31: 564-570
  114. Sullivan MD Edlund MJ Zhang L Unützer J Wells KB: Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med 2006; 166: 2087-2093
  115. Edlund MJ Martin BC Devries A Fan MY Braden JB Sullivan MD: Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain 2010; 26: 1-8
  116. Kidner CL Gatchel RJ Mayer TG: MMPI disability profile is associated with degree of opioid use in chronic work-related musculoskeletal disorders. Clin J Pain 2010; 26: 9-15
  117. Hasin DS Goodwin RD Stinson FS Grant BF: Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62: 1097-1106
  118. Huang B Dawson DA Stinson FS Hasin DS Ruan WJ Saha TD Smith SM Goldstein RB Grant BF: Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67: 1062-1073
  119. Nedeljkovic SS Wasan A Jamison RN: Assessment of efficacy of long-term opioid therapy in pain patients with substance abuse potential. Clin J Pain 2002; 18: S39-S51
  120. Strain EC: Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain 2002; 18: S14-S27
  121. Grant BF Stinson FS Dawson DA Chou SP Dufour MC Compton W Pickering RP Kaplan K: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61: 807-816
  122. Toblin RL Paulozzi LJ Logan JE Hall AJ Kaplan JA: Mental illness and psychotropic drug use among prescription drug overdose deaths: a medical examiner chart review. J Clin Psychiatry 2010; 71: 491-496
  123. Brown RJ: Psychological mechanisms of medically unexplained symptoms: an integrative conceptual model. Psychol Bull 2004; 130: 793-812
  124. Rief W Barsky AJ: Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology 2005; 30: 996-1002
  125. McHugh PR Slavney PR: Methods of reasoning in psychopathology: conflict and resolution. Compr Psychiatry 1982; 23: 197-215
  126. McHugh PR: A structure for psychiatry at the century’s turn: the view from Johns Hopkins. J R Soc Med 1992; 85: 483-487
  127. Clark MR: Psychiatry and chronic pain: examining the interface and designing a structure for a patient-centered approach to treatment. Eur J Pain 2009; 13: ((suppl)) 95-100
  128. McHugh PR Slavney PR: Perspectives of Psychiatry, ed 2. Baltimore, Johns Hopkins University Press, 1998;
  129. Slavney PR: Perspectives on ‘Hysteria’. Baltimore, Johns Hopkins University Press, 1990;
  130. Reuber M Mitchell AJ Howlett SJ Crimlisk HL Grunewald RA: Functional symptoms in neurology: questions and answers. J Neurol Neurosurg Psychiatry 2005; 76: 307-314
  131. Clark MR: Psychogenic disorders: a pragmatic approach for formulation and treatment. Sem Neurol 2006; 26: 357-365
  132. Clark MR Treisman GJ: Perspectives on pain and depression. Adv Psychosom Med 2004; 25: 1-27
  133. Stone J Carson A Sharpe M: Functional symptoms and signs in neurology: management. J Neurol Neurosurg Psychiatry 2005; 76: ((suppl 1)) i13-i21
  134. Rief W Nanke A: Somatoform disorders in primary care and inpatient settings. Adv Psychosom Med 2004; 26: 144-158
  135. King VL Peirce J Brooner RK Kidorf M: Predictors of treatment enrollment in syringe exchange participants. Presented at College on Problems of Drug Dependence Scientific Meeting, Quebec City 2007;
  136. Brooner RK King V Neufeld K Stoller K Peirce J Kidorf M Clark M Aklin W: Integrated psychiatric services are associated with improved service delivery and better treatment response. Presented at College on Problems of Drug Dependence 70th Annual Scientific Meeting, San Juan 2008;
  137. Umbricht-Schneiter A Ginn DH Pabst KM Bigelow GE: Providing medical care to methadone clinic patients: referral vs on-site care. Am J Public Health 1994; 84: 207-210
  138. Svikis DS Silverman K Hauq NA Stitzer M Keyser-Marcus L: Behavioral strategies to improve treatment participation and retention by pregnant drug-dependent women. Subst Use Misuse 2007; 42: 1527-1535
  139. Flor H Fydrich T Turk DC: Efficacy of multidisciplinary pain treatment centers: a meta-analytic review. Pain 1992; 49: 221-230
  140. Haythornthwaite JA: Clinical trials studying pharmacotherapy and psychological treatments alone and together. Neurology 2005; 65: 20-31
  141. Maruta T Malinchoc M Offord KP Colligan RC: Status of patients with chronic pain 13 years after treatment in a pain management center. Pain 1998; 74: 199-204
  142. Morley S Eccleston C Williams A: Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 1999; 80: 1-13
  143. Turk DC Okifuji A: Psychological factors in chronic pain: evolution and revolution. J Consult Clin Psychol 2002; 70: 678-690
  144. Brooner RK Kidorf M: Using behavioral reinforcement to improve methadone treatment participation. Sci Pract Perspect 2002; 1: 38-46
  145. Brooner RK Kidorf MS King VL Stoller KB Peirce JM Bigelow GE Kolodner K: Behavioral contingencies improve counseling attendance in an adaptive treatment model. J Subst Abuse Treat 2004; 27: 223-232
  146. Brooner RK Kidorf MS King VL Stoller KB Neufeld KJ Kolodner K: Comparing adaptive stepped care and monetary-based voucher incentives for opioid dependence. Drug Alcohol Depend 2007; 88: ((suppl 2)) S14-S23
  147. Clark MR Stoller KB Brooner RK: Assessment and management of chronic pain in individuals seeking treatment for opioid dependence disorder. Can J Psychiatry 2008; 53: 496-508

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50